Heat shock protein 90 (HSP90) is an ATP-dependent molecular chaperone essential in eukaryotic organisms.

This article summarized the latest R&D progress of Finerenone, the Mechanism of Action for Finerenone, and the drug target R&D trends for Finerenone.

Pfizer Inc. confirmed the received marketing approval by the EC for LITFULO™ (ritlecitinib)  aimed for the treatment of severe alopecia areata in adults and adolescents aged 12 years and above.

This article summarized the latest R&D progress of Etonogestrel, the Mechanism of Action for Etonogestrel, and the drug target R&D trends for Etonogestrel.

Histamine receptors are proteins found in various tissues throughout the human body.

This article summarized the latest R&D progress of Estradiol valerate, the Mechanism of Action for Estradiol valerate, and the drug target R&D trends for Estradiol valerate.

Heidelberg Pharma AG announced it began patient recruitment for the fifth group in the Phase I/IIa trial of their main development candidate, HDP-101, with a dose of 100 µg/kg.

This article summarized the latest R&D progress of Diazoxide, the Mechanism of Action for Diazoxide, and the drug target R&D trends for Diazoxide.

Heparin is a naturally occurring anticoagulant that plays a crucial role in the human body's blood clotting process.

This article summarized the latest R&D progress of Brompheniramine maleate, the Mechanism of Action for Brompheniramine maleate, and the drug target R&D trends for Brompheniramine maleate.

Orexo AB recently submitted its NDA to the US FDA for OX124, a high-dose, nasally-administered treatment for opioid overdoses.

This article summarized the latest R&D progress of Lomustine, the Mechanism of Action for Lomustine, and the drug target R&D trends for Lomustine.